Abstract |
In a multi-institutional study 26 patients with refractory acute myeloid leukemia were entered into a phase I/II study of HD- ara-C and mitox. HD- ara-C 3 g/m2 q 12h was given by 3h infusion on days 1-4. Mitox was started at 12 mg/m2/d on days 3, 4 and 5, and escalated to 4 and 5 doses of 10 mg/m2/d on days 2-5 and 2-6, respectively. From 24 patients presently evaluable for response, 12 achieved a CR and 2 a PR. 7 patients died of infectious complications within the first 4 weeks of treatment while persistent AML was found in 3 cases. Except for one death, possibly related to acute cardiomyopathy, toxicity was mild to moderate consisting of nausea and vomiting, mucositis and diarrhea. These data indicate a high anti-leukemic activity of HD- ara-C/ mitox in AML refractory against conventional chemotherapy.
|
Authors | W Hiddemann, H Kreutzmann, K Straif, W D Ludwig, R Donhuijsen-Ant, E Lengfelder, Z Arlin, T Büchner |
Journal | Onkologie
(Onkologie)
Vol. 9
Issue 3
Pg. 144-6
(Jun 1986)
ISSN: 0378-584X [Print] Switzerland |
PMID | 3528960
(Publication Type: Journal Article)
|
Chemical References |
- Anthraquinones
- Antineoplastic Agents
- Cytarabine
- Mitoxantrone
|
Topics |
- Anthraquinones
(administration & dosage)
- Antineoplastic Agents
(administration & dosage)
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Cytarabine
(administration & dosage)
- Dose-Response Relationship, Drug
- Drug Evaluation
- Drug Resistance
- Humans
- Leukemia, Myeloid, Acute
(drug therapy)
- Mitoxantrone
- Prognosis
|